Association between patient characteristics and AHA
| Factor* . | No AHA . | AHA . | P . |
|---|---|---|---|
| Age, no. (%) | |||
| Younger than 60 y | 231 (93) | 17 (7) | .03 |
| 60 to 69 y | 256 (90) | 28 (10) | |
| 70 y or older | 195 (86) | 32 (14) | |
| Stage, no. (%) | |||
| A progressive | 176 (93) | 13 (7) | <.001 |
| B | 324 (94) | 20 (6) | |
| C | 182 (81) | 44 (19) | |
| Sex, no. (%) | |||
| Female | 180 (90) | 19 (10) | .8 |
| Male | 502 (90) | 58 (10) | |
| Treatment, no. (%) | |||
| Chlorambucil | 330 (88) | 47 (12) | .008 |
| Fludarabine | 169 (89) | 21 (11) | |
| FC | 183 (95) | 9 (5) | |
| DAT at entry, no. (%) | |||
| Positive | 63 (72) | 25 (28) | <.001† |
| Negative | 493 (92) | 40 (8) | |
| Unknown/missing | 126 (91) | 12 (9) | |
| B2M, mg/L, median (range), n = 546 | 3.6 (0.0–12.2) | 4.9 (1.3–12.7) | < .001‡ |
| ALC, ×109/L, median (range), n = 734 | 77 (1–568) | 94 (1–570) | .2‡ |
| LDH, U/L, median (range), n = 684 | 415 (69–1953) | 420 (4–1295) | .6‡ |
| Factor* . | No AHA . | AHA . | P . |
|---|---|---|---|
| Age, no. (%) | |||
| Younger than 60 y | 231 (93) | 17 (7) | .03 |
| 60 to 69 y | 256 (90) | 28 (10) | |
| 70 y or older | 195 (86) | 32 (14) | |
| Stage, no. (%) | |||
| A progressive | 176 (93) | 13 (7) | <.001 |
| B | 324 (94) | 20 (6) | |
| C | 182 (81) | 44 (19) | |
| Sex, no. (%) | |||
| Female | 180 (90) | 19 (10) | .8 |
| Male | 502 (90) | 58 (10) | |
| Treatment, no. (%) | |||
| Chlorambucil | 330 (88) | 47 (12) | .008 |
| Fludarabine | 169 (89) | 21 (11) | |
| FC | 183 (95) | 9 (5) | |
| DAT at entry, no. (%) | |||
| Positive | 63 (72) | 25 (28) | <.001† |
| Negative | 493 (92) | 40 (8) | |
| Unknown/missing | 126 (91) | 12 (9) | |
| B2M, mg/L, median (range), n = 546 | 3.6 (0.0–12.2) | 4.9 (1.3–12.7) | < .001‡ |
| ALC, ×109/L, median (range), n = 734 | 77 (1–568) | 94 (1–570) | .2‡ |
| LDH, U/L, median (range), n = 684 | 415 (69–1953) | 420 (4–1295) | .6‡ |